| INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disorders characterised by hepatic lipid accumulation and cellular degeneration, in the absence of significant alcohol consumption or secondary causes of hepatic steatosis. 1 NAFLD includes those with nonalcoholic steatohepatitis (NASH), who are most likely to develop progressive fibrosis, cirrhosis and hepatocellular carcinoma. The prevalence of NAFLD is 10%-25% in the general population, and increases to~75% in patients with obesity and diabetes. [1] [2] [3] Currently, the most widely accepted view of the pathogenesis of NAFLD is based on a "two-hit," or a "multiple-hit" model, with insulin resistance leading to hepatic lipid accumulation, representing the first hit. Successive activation of multiple pathways resulting in oxidative and inflammatory stress are thought to represent additional hit(s) which mediate progression of disease and fibrosis; 4, 5 among individuals with NAFLD, 23.8% are reported to have ≥F2 fibrosis and 2.3%-9.7% exhibit ≥F3 fibrosis. 6 However, despite the pivotal role of insulin resistance in the pathogenesis of NAFLD, improving insulin sensitivity with metformin has only a minimal independent effect on liver histology and therefore is not clinically recommended. 1, 7 There is some evidence that pioglitazone improves NASH; 8, 9 however, that primary outcome measure was not achieved in a large clinical trial. 8 Furthermore, effects reported with pioglitazone do not appear to be a thiazolidinedione-class effect, as rosiglitazone has not been effective in multiple clinical trials. 9, 10 There are presently no FDAapproved therapeutic agents for treatment of NASH, although weight loss exceeding 5%, whether via hypocaloric diet, exercise or both improve hepatic steatosis, and more substantial weight loss (~10%) may improve necroinflammation (sustained inflammation leading to necrosis and fibrosis) as well.
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The 5 0 adenosine monophosphate-activated protein kinase (AMPK)/Sirtuin 1 (Sirt1) pathway is a key regulator of mitochondrial biogenesis, energy and lipid metabolism, including hepatic lipid metabolism. [12] [13] [14] [15] [16] [17] Activation of this pathway via either enzyme prevents or reverses excess hepatic lipid accumulation and inflammation, [18] [19] [20] [21] [22] thus representing possible therapeutic targets for NASH. We have demonstrated that L-leucine has a unique role as an activator of the Sirt1/AMPK pathway, 14, 23, 24 serving as a partial mimetic of caloric restriction in pre-clinical models, and thereby modulates lipid and energy metabolism and increases insulin sensitivity.
Consequently, adding L-leucine to metformin results in a novel, synergistic interaction that enabled a 65%-80% metformin dose reduction with no loss of anti-diabetic efficacy in diabetic rodent models 25, 26 and a 40% metformin dose reduction in a recent clinical trial. 27 Moreover, this combination of leucine with low-dose metformin reversed hepatic steatosis in pre-clinical studies in murine models of type 2 diabetes and NASH despite the lack of observed effect of full-dose metformin in the absence of L-leucine, 28 and adding low-dose sildenafil synergistically enhances this effect by stimulating endothelial nitric oxide synthase (eNOS) activity leading to further stimulation of Sirt1, and thus further attenuating inflammation and fibrosis. 15, 29 Accordingly, this exploratory phase 2 study was conducted to evaluate the efficacy of NS-0200, a leucinemetformin-sildenafil fixed-dose combination, in reducing hepatic steatosis and improving related metabolic parameters in a placebocontrolled multicentre 16-week clinical trial.
| METHODS

| Study design
This was a randomised, placebo-controlled, phase 2, double-blind study designed to evaluate the effects on hepatic steatosis of 2 fixed-dose combinations of leucine, metformin and sildenafil (NS-0200) administered twice daily for 16 weeks, compared to placebo (NCT 02546609). Active treatments consisted of capsules containing 1100 mg leucine, 500 mg metformin and either 0.5 or 1.0 mg sildenafil administered twice daily orally (Table 1) .
Subjects were screened at clinical sites for basic eligibility criteria with a detailed medical history and physical examination and blood analysis 14 days prior to initiating the study. Those subjects who met eligibility criteria returned for a screening magnetic resonance imaging (MRI) exam to estimate hepatic fat fraction by proton-density fat fraction (PDFF) within 7 days prior to study initiation. Participants with hepatic fat fraction ≥15% by MRI-PDFF were enrolled in the study.
Participants who qualified by MRI-PDFF returned to the clinic on study day 1 for baseline laboratories and first dose of study medication, followed by visits on days 7, 28, 56, 84 and 112 (end of study).
Subjects were also contacted by telephone on days 14, 42, 70 and 98 to enhance compliance. Study visits included routine blood tests, body weight and assessment of compliance via pill counts, and the final study visit included the endpoint MRI to assess PDFF change.
This study was approved by the Institutional Review Boards at each participating centre, and written informed consent was obtained from all participants prior to study enrolment and initiation of study-specific procedures.
| Eligibility
The key inclusion criteria were age 18-75 years at study entry, MRI-PDFF ≥15%, ALT ≥ 30 U/L for men and ≥ 19 U/L for women, body mass index between 25 and 40 kg/m 2 and clinical and laboratory criteria consistent with NAFLD. Subjects with evidence of other chronic liver disease or with history of significant alcohol consumption, defined as >7 drinks/wk for both males and females for the prior 6 months were excluded from the trial.
| Randomisation and blinding
A computer-generated randomised block schedule was prepared by a third party, and treatment allocation was performed centrally for all sites, with randomization numbers assigned in chronological order.
Study medication was provided to study centres in a blinded manner, and sponsor personnel, study staff, MRI analysis staff and subjects were blinded to treatment assignment.
| Primary and secondary outcomes
The primary outcome was 16- 
| MRI acquisition
An MRI of the liver was performed using a torso-array surface coil centred over the upper abdomen using one or both types of breathhold, noncontrast, gradient-recalled-echo, axial 2D sequence: a multiple-echo (ME) 6-echo sequence, and a double-double-echo (DDE)
sequence. MRI-PDFF results from these2 types of sequence have been shown to be nearly identical. 30 Target MRI scanning parameters were selected to avoid or correct for possible confounding factors (eg, T1 bias, T2* decay, multi-frequency interference) that could introduce error in fat quantification. [31] [32] [33] [34] [35] [36] 
| MRI QC and analysis
After intake QC inspection of images and DICOM-header parameter information, 3 circular, 1-cm radius regions of interest (ROIs) were placed in the right lobe of liver, preferentially on fifth-echo liver images for the ME sequence, and on the first-echo liver images of the first DDE sequence, avoiding major vessels and ducts, lesions, artefact, other organs and liver edges. Those ROIs were propagated to images for the other echoes. ROI signal intensities from those images were analysed with the MATLAB software analysis package (MathWorks, Natick, MA) using a custom fitting algorithm that assumed exponential T2* signal decay, and applied a multi-peak spectral model to account for fat-fat and fat-water multi-frequency interference effects, based on the work of Hamilton et al. 37 39 Metabolomics data were pre-processed using the TargetLynx application manager for MassLynx 4.1 (Waters Corp., Milford, MA). Intra-batch (multiple internal standard response corrections) and inter-batch (variable specific interbatch single point external calibration using repeat extracts of a commercial serum sample) data normalisation is described in. 40 
| Safety evaluation
Safety assessment included physical examination with vital signs, 12-lead electrocardiogram, clinical chemistry, haematology and urinalysis. Adverse events were categorised by severity, outcome and relationship to study drug.
| Statistics
The primary analysis population was per protocol (PP) for efficacy endpoints and intention to treat (ITT) for safety endpoints. The PP population consisted of all ITT subjects who completed all study visits, had a valid MRI measured at the endpoint and who adequately complied with the study protocol without major protocol deviations and received ≥ 80% of provided study medication via pill counts. A 
T A B L E 1 Treatment arms
| RESULTS
Two hundred and fifteen subjects were screened for participation.
124 of these did not meet enrolment criteria, primarily due to hepatic fat fraction <15%. The remaining 91 subjects were randomised, 24 to placebo (treatment group A), 35 to the 1100 mg leucine/ 500 mg metformin/0.5 mg sildenafil group (treatment group B) and 32 to the 1100 mg leucine/500 mg metformin/1.0 mg sildenafil group (treatment group C). Of these, 90 participants received at least one dose of medication and constituted the ITT analysis group.
Twenty of the enrolled (22.0%) participants discontinued study treatment early; 2 from placebo (treatment group A, 8.3%), 11 (31.4%) from treatment group B and 7 (21.9%) from treatment group C. Of the 71/91 (78.0%) participants completing the trial, 1 was excluded from the PP analysis group due to non-adherence with a priori study medication compliance criteria. Thus, a total of 70 participants were analysed for this study for the PP group. Participants' baseline characteristics are shown in Table2.
The relative change in MRI-PDFF between baseline and end of treatment was À10 AE 17.5% in the placebo treated patients, whereas it was 3.08 AE 25.5% in low-dose NS-0200-treated patients (P = 0.057 compared to placebo) and À4.01 AE 24.6% in high-dose NS-0200-treated patients (P = 0.377 compared to placebo) (Figure 1 ). There were no significant changes in ALT, AST, GGT or K18 Figure S3 ).
Treatment-emergent adverse events (TEAEs) are summarised in Table 3 . Overall, the frequency of TEAEs was similar between placebo (75% of subjects) and pooled treatment groups (77% of subjects). Similarly, comparable fractions of placebo (50%) and active treatment (54.5%) subjects reported TEAEs that were considered related to study treatment (Table 3) . However, subjects in the active treatment groups did report a greater number of mild-to-moderate gastrointestinal events than the placebo group, including diarrhoea (40.9 vs 8.3%), nausea (16.7 vs 12.5%) and vomiting (4.2 vs 0.6%), consistent with the presence of metformin. There were no (0.0%) serious TEAEs that were related to study treatment in any of the treatment groups (placebo or NS-0200).
Subjects discontinued participation in the trial for the following reasons: noncompliance/protocol violation(s), n = 5; withdrawal of consent, n = 3; lost to follow-up, n = 5; and TEAEs, n = 7. TEAEs leading to discontinuation are summarised in Table 4 . Two doses of NS-0200 were evaluated, both containing 1.11 g leucine and 500 mg metformin, and differing from each other only in the quantity of sildenafil present (0.5 vs 1.0 mg). These sildenafil doses were extrapolated from rodent data, 15 accounting for species differences in bioavailability. The lower dose produced little effect on most variables, although it did result in improvements in the metabolomics profile, while the higher dose produced improvement in multiple variables. Thus, these data do not permit a conclusion with respect to optimal sildenafil dose, and higher doses may be warranted in follow-up studies. However, rodent studies (unpub- 48 Further increases in leucine administration result in a slower increase, plateauing at~0.8 mM, 48 but this higher level is associated with potential mTOR activation, while 0.5 mM leucine is not. 25 The metformin dose in NS-0200 is based on a previous assessment of leucine-metformin synergy in improving glycemic control in patients with type 2 diabetes. 27 The combination of leucine, metformin and sildenafil in NS-0200 targets a synergistic interaction among elements of the Sirt1-AMPKeNOS network. 15 This network is a key regulator of integral factors Green sections of the heat map denote metabolites that were reduced (negative log 2 fold-changes) and red sections denote metabolites that were increased (positive log 2 fold-changes); grey/black bars indicate significant changes with treatment (light grey, P < 0.05; dark grey, P < 0.01; black, P < 0.001) Green sections of the heat map denote metabolites that were reduced (negative log 2 fold-changes) and red sections denote metabolites that were increased (positive log 2 foldchanges); grey/black bars indicate significant changes with treatment (light grey, P < 0.05; dark grey, P < 0.01; black, P < 0.001) children to adolescents also indicate little to no independent effect of metformin; metformin exerted no effect on reducing ALT, hepatic steatosis, lobular inflammation, NAFLD activity score or resolution of NASH in the 96-week multicentre randomised trial (TONIC Trial) of 173 patients aged 8-17 years, although there was an improvement in ballooning degeneration score. Treatment-emergent adverse event (TEAE) is defined as an adverse event occurring on or after the first dose of randomised study medication, or existing prior to the time of and worsening after the time of the first dose of randomised study medication.
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Although leucine has not been well-studied in NASH, pre-clinical data demonstrate little or no independent effect of leucine on either histology or relevant biomarkers in mouse models of NAFLD/ NASH. 15, 29 Similarly, pre-clinical data demonstrate greater efficacy of the leucine-metformin-sildenafil combination compared to combinations of any two of these agents (leucine-metformin, leucine-sildenafil, metformin-sildenafil) in regressing hepatic steatosis, inflammation and fibrosis in a mouse model of NASH. 15 Thus, the efficacy of this p<0.05 Green sections of the heat map denote metabolites that were reduced (negative log 2 fold-changes) and red sections denote metabolites that were increased (positive log 2 fold-changes); grey/black bars indicate significant changes with treatment (light grey, P < 0.05; dark grey, P < 0.01; black, P < 0.001) combination appears to be dependent upon synergistic interaction among leucine, metformin and sildenafil.
Overall, NS-0200 was well-tolerated in this trial, with no difference in TEAEs in treatment vs placebo groups, although subjects in the active treatment groups reported a greater number of mild-to-moderate gastrointestinal events than the placebo group, consistent with the metformin component of NS-0200.
This study has several limitations. Since the study was an exploratory proof-of-concept study of relatively short duration, liver biopsies could not be justified and therefore fibrosis and other histological outcomes cannot be assessed. Additionally, since subjects were selected on the basis of MRI-PDFF (a quantitative biomarker of hepatic steatosis) rather than biopsy-proven NASH, our study probably included individuals with mild NAFLD unlikely to respond to intervention. Additionally, the metabolomics data indicate heterogeneity in the extent of disease, with the placebo group presenting a metabolic signature demonstrating lower levels of relevant metabolically active lipids (DG, TG, cholesterol esters, glycerophospholipids, ceramides and sphingomyelins) than the 2 active treatment groups ( Figure 5 ), suggesting less advanced disease and possibly contributing to greater volatility in MRI-PDFF in the placebo vs active treatment groups in the full cohort (per protocol) placebo group.
In conclusion, high-dose NS-0200 significantly reduced hepatic fat in NAFLD patients with elevated ALT, and correspondingly improved the NAFLD-associated metabolomic signature. NS-0200, either in high or low dose, did not improve hepatic fat in the ITT population, but the placebo-treated participants exhibited an unusually high response rate. These data support further development of NS-0200, especially high-dose NS-0200 in NAFLD patients with elevated ALT.
